Amazon launches GLP-1 weight loss program
Amazon GLP-1 treatment
Source: Amazon Inc.
Amazon is pushing deeper into the booming weight loss market, unveiling a new program Tuesday that aims to make popular GLP-1 treatments easier to access.
The company announced that Amazon One Medical, its primary care arm, is launching a GLP-1 management program that integrates obesity treatment into routine care. The offering combines virtual and in-person visits, prescription management and pharmacy fulfillment, positioning weight management as a long-term chronic condition rather than a one-time prescription.
“Providing customers with fast, convenient access to medications and clear, transparent pricing is a key driver in how Amazon Pharmacy is transforming the pharmacy experience,” Tanvi Patel, vice president and general manager of Amazon Pharmacy, said in the company’s press release.
“By expanding access to the latest GLP-1 medicines with clear, upfront pricing, we are making it easier for customers to receive the treatments prescribed by their healthcare providers and continue taking these medicines because they are reliably delivered directly to patients,” said Patel.
Patients can access medication, among other things, via Amazon Pharmacy Novo Nordisks Wegovy as well as newer oral GLP-1 options. According to Amazon, insured prices start at just $25 per month. For cash-paying patients, oral medications start at $149 per month, it said.
Injectable treatments, including Wegovy shots and Eli Lilly’s Zepbound starts at $299 per month when paid without insurance, Amazon said.
These prices are roughly in line with much of the current market.
However, Amazon’s advantage lies in same-day delivery and convenience as the company looks to leverage its logistics network and customer reach in a different part of the medical system.
The company also said it will offer on-demand prescription renewals, starting at $29 for message consultation and $49 for video care. Amazon plans to expand its same-day drug delivery offering to 4,500 cities by the end of 2026.
Shares of several companies linked to the obesity drug boom fell after Amazon’s announcement on Tuesday, including Health for him and her, Viking Therapeutics, Amgen And Septerna.
Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
